Grace Therapeutics Inc. (GRCE) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Grace Therapeutics Inc.

NASDAQ: GRCE · Real-Time Price · USD
3.02
0.00 (0.00%)
At close: Oct 03, 2025, 3:59 PM
3.01
-0.50%
After-hours: Oct 03, 2025, 05:50 PM EDT

Grace Therapeutics Income Statement

Financials in USD. Fiscal year is April - March.
Fiscal Year Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020
Revenue
n/a 8K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 115K 81K n/a n/a
Cost of Revenue
2K n/a 2K 2K 1K 1K 1K 2K n/a n/a n/a n/a n/a n/a n/a n/a n/a 40K 36K n/a n/a
Gross Profit
-2K 5K -2K -2K -1K -1K -1K -2K n/a n/a n/a n/a n/a n/a n/a n/a n/a 75K 45K n/a n/a
Operating Income
-3.09M -3.18M -3.7M -4.83M -4.96M -3.26M -3.04M -2.09M -4.45M -38.07M -4.25M -5.11M -4.73M -4.4M -4.47M -3.57M -3.15M -2.3M -1.96M -8.03M -4.12M
Interest Income
205K 167K 138K 172K 235K 249K 316K 212K 134K 187K 67K 36K 32K 114K 40K 14K 20K 30K 38K 15K 25K
Pretax Income
-3.36M -382K -4.76M -4.28M -3.34M -4.05M -2.6M -3.72M -4.31M -37.96M -4.16M -5.08M -4.77M -4.55M -3.78M 981K -3.12M -5.65M -3.22M -6.15M -4.67M
Net Income
-3.36M 636K -4.16M -3.43M -2.62M -3.17M -2.39M -3.27M -4.02M -29.09M -3.89M -4.93M -4.52M -3.9M -3.78M 981K -3.12M -5.65M -3.22M -6.15M -4.67M
Selling & General & Admin
2.13M 1.55M 1.51M 1.85M 2.25M 1.54M 1.6M 1.63M 1.87M 2.52M 1.77M 1.83M 2.09M 2.08M 2.05M 2.98M 2.68M 1.51M 1.33M 1.45M 2.37M
Research & Development
955K 1.63M 2.19M 2.98M 2.71M 1.69M 1.44M 460K 1.09M 1.64M 2.45M 3.29M 2.59M 2.33M 2.18M 585K 469K 453K 678K 1.29M 1.21M
Other Expenses
n/a 2K 1K 2K 1K 35K n/a 1K 1.49M 33.92M 20K -12K 46K n/a 249K n/a n/a 413K n/a 5.29M 545K
Operating Expenses
3.09M 3.18M 3.7M 4.83M 4.96M 3.26M 3.04M 2.09M 4.45M 38.07M 4.25M 5.11M 4.73M 4.4M 4.47M 3.57M 3.15M 2.38M 2.01M 8.03M 4.12M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a 75K n/a n/a n/a 147K n/a n/a n/a 264K n/a n/a 121K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a 61K 30K n/a n/a 51K 72K 3K 10K 255K 78K n/a n/a 66K 226K -67K 716K
Cost & Expenses
3.09M 3.18M 3.7M 4.83M 4.96M 3.26M 3.04M 2.09M 4.45M 38.07M 4.25M 5.11M 4.73M 4.4M 4.47M 3.57M 3.15M 2.42M 2.04M 8.03M 4.12M
Income Tax Expense
n/a -1.02M -605K -852K -724K -889K -208K -446K -289K -8.87M -274K -155K -242K -648K n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
15.92M 13.72M 11.51M 11.51M 10.93M 9.18M 7.49M 7.55M 7.44M 7.44M 7.43M 7.42M 7.39M 6.76M 7.38M 5.46M 4.34M 3.41M 2.09M 1.98M 1.89M
Shares Outstanding (Diluted)
15.92M 13.72M 11.51M 11.51M 10.93M 9.18M 7.49M 7.55M 7.44M 7.44M 7.43M 7.42M 7.39M 6.76M 7.38M 5.46M 4.34M 3.41M 2.09M 1.98M 1.89M
EPS (Basic)
-0.21 0.05 -0.36 -0.3 -0.24 -0.34 -0.32 -0.43 -0.54 -3.91 -0.52 -0.66 -0.61 -0.58 -0.54 0.18 -0.72 -1.66 -1.56 -3.12 -2.4
EPS (Diluted)
-0.21 0.05 -0.36 -0.3 -0.24 -0.34 -0.32 -0.43 -0.54 -3.91 -0.52 -0.66 -0.61 -0.58 -0.54 0.18 -0.72 -1.66 -1.56 -3.12 -2.4
EBITDA
-3.36M -3.18M -3.7M -4.83M -4.96M -4.05M -3.04M -2.09M -2.96M -4.16M -4.22M -5.12M -4.56M -4.4M -4.22M -3.57M -3.15M -5.64M -1.96M -2.37M -3.57M
EBIT
-3.36M -3.18M -3.7M -4.83M -4.96M -3.26M -3.04M -2.09M -2.97M -4.17M -4.25M -5.11M -4.73M -4.4M -4.22M -3.57M -3.15M -5.65M -1.96M -2.74M -4.12M
Depreciation & Amortization
2K 2K 2K 2K 1K 1K 1K 2K 7K 8K 10K -61K 167K n/a n/a n/a n/a 1K n/a 375K 548K